全文获取类型
收费全文 | 147701篇 |
免费 | 43939篇 |
国内免费 | 1147篇 |
专业分类
耳鼻咽喉 | 1829篇 |
儿科学 | 5388篇 |
妇产科学 | 1440篇 |
基础医学 | 25880篇 |
口腔科学 | 6796篇 |
临床医学 | 20756篇 |
内科学 | 30806篇 |
皮肤病学 | 4496篇 |
神经病学 | 25542篇 |
特种医学 | 6562篇 |
外国民族医学 | 1篇 |
外科学 | 16608篇 |
综合类 | 4331篇 |
现状与发展 | 8篇 |
一般理论 | 10篇 |
预防医学 | 12730篇 |
眼科学 | 1416篇 |
药学 | 11532篇 |
35篇 | |
中国医学 | 3628篇 |
肿瘤学 | 12993篇 |
出版年
2024年 | 192篇 |
2023年 | 858篇 |
2022年 | 1632篇 |
2021年 | 3683篇 |
2020年 | 7885篇 |
2019年 | 13054篇 |
2018年 | 12604篇 |
2017年 | 13773篇 |
2016年 | 12928篇 |
2015年 | 12544篇 |
2014年 | 13517篇 |
2013年 | 14675篇 |
2012年 | 12327篇 |
2011年 | 12129篇 |
2010年 | 10501篇 |
2009年 | 6876篇 |
2008年 | 7377篇 |
2007年 | 5729篇 |
2006年 | 5376篇 |
2005年 | 4916篇 |
2004年 | 4667篇 |
2003年 | 4187篇 |
2002年 | 3968篇 |
2001年 | 3057篇 |
2000年 | 1795篇 |
1999年 | 573篇 |
1998年 | 323篇 |
1997年 | 273篇 |
1996年 | 210篇 |
1995年 | 149篇 |
1994年 | 158篇 |
1993年 | 128篇 |
1992年 | 111篇 |
1991年 | 94篇 |
1990年 | 71篇 |
1989年 | 49篇 |
1988年 | 45篇 |
1987年 | 59篇 |
1986年 | 43篇 |
1985年 | 42篇 |
1984年 | 46篇 |
1983年 | 41篇 |
1982年 | 30篇 |
1981年 | 22篇 |
1980年 | 16篇 |
1979年 | 19篇 |
1978年 | 10篇 |
1977年 | 12篇 |
1976年 | 6篇 |
1975年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Louise Danielsson RPT MSc Susanne Rosberg RPT PhD 《Scandinavian journal of caring sciences》2015,29(3):501-509
Although depression is associated to physical discomfort, meanings of the body in depression are rarely addressed in clinical research. Drawing on the concept of the lived body, this study explores depression as an embodied phenomenon. Using a hermeneutic phenomenological approach, the analysis of narrative‐based interviews with 11 depressed adults discloses a thematic structure of an embodied process of an ambiguous striving against fading. Five subthemes elicit different dimensions of this process, interpreted as disabling or enabling: feeling estranged, feeling confined, feeling burdensome, sensing life and seeking belongingness. In relation to clinical practice, we suggest that the interdisciplinary team can focus on enhancing the enabling dimensions, for example through guided physical activities to support the patient to feel more alive, capable and connected. Moreover, we suggest that the treatment process benefits from an increased awareness of the ambiguity in the patient's struggle, acknowledging both destructive and recharging elements of the withdrawing, and the perceived conflict in‐between. 相似文献
2.
3.
4.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions 下载免费PDF全文
5.
Interprofessional collaboration and communication in nursing homes: a qualitative exploration of problems in medical care for nursing home residents – study protocol 下载免费PDF全文
6.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文
7.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
8.
9.
10.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献